Alignment Healthcare (ALHC) Projected to Post Quarterly Earnings on Thursday

Alignment Healthcare (NASDAQ:ALHC) is expected to be issuing its Q4 2025 results after the market closes on Thursday, February 26th. Analysts expect the company to announce earnings of ($0.15) per share and revenue of $1.0034 billion for the quarter. Individuals are encouraged to explore the company’s upcoming Q4 2025 earning overview page for the latest details on the call scheduled for Thursday, February 26, 2026 at 5:00 PM ET.

Alignment Healthcare Stock Down 0.4%

Shares of Alignment Healthcare stock opened at $20.51 on Thursday. Alignment Healthcare has a one year low of $11.63 and a one year high of $23.87. The company has a market cap of $4.10 billion, a P/E ratio of -170.92, a PEG ratio of 5.25 and a beta of 1.16. The company has a debt-to-equity ratio of 1.99, a quick ratio of 1.61 and a current ratio of 1.61. The firm has a fifty day moving average of $20.98 and a two-hundred day moving average of $18.25.

Wall Street Analyst Weigh In

A number of equities research analysts recently commented on ALHC shares. Weiss Ratings restated a “sell (d-)” rating on shares of Alignment Healthcare in a research report on Wednesday, January 21st. UBS Group increased their target price on Alignment Healthcare from $18.00 to $21.00 and gave the stock a “neutral” rating in a research note on Wednesday, January 14th. Barclays lifted their price target on Alignment Healthcare from $13.00 to $18.00 and gave the company an “equal weight” rating in a research note on Friday, October 31st. The Goldman Sachs Group reissued a “buy” rating and issued a $22.00 target price on shares of Alignment Healthcare in a report on Monday, November 3rd. Finally, KeyCorp reaffirmed an “overweight” rating and set a $28.00 price target on shares of Alignment Healthcare in a research note on Thursday, January 22nd. One equities research analyst has rated the stock with a Strong Buy rating, nine have assigned a Buy rating, three have given a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, Alignment Healthcare currently has an average rating of “Moderate Buy” and an average price target of $23.32.

Insider Activity

In related news, CEO John E. Kao sold 605,648 shares of the business’s stock in a transaction dated Monday, December 29th. The shares were sold at an average price of $18.74, for a total value of $11,349,843.52. Following the sale, the chief executive officer directly owned 2,234,294 shares in the company, valued at $41,870,669.56. The trade was a 21.33% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider Robert L. Scavo sold 69,541 shares of the stock in a transaction dated Monday, December 29th. The shares were sold at an average price of $18.74, for a total transaction of $1,303,198.34. Following the completion of the sale, the insider directly owned 503,014 shares in the company, valued at approximately $9,426,482.36. The trade was a 12.15% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold a total of 2,150,938 shares of company stock worth $42,274,570 over the last 90 days. 7.00% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

Hedge funds have recently modified their holdings of the business. Royal Bank of Canada raised its position in shares of Alignment Healthcare by 92.6% during the 1st quarter. Royal Bank of Canada now owns 92,379 shares of the company’s stock worth $1,720,000 after purchasing an additional 44,413 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its position in Alignment Healthcare by 4.6% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 59,557 shares of the company’s stock worth $1,109,000 after buying an additional 2,594 shares in the last quarter. Goldman Sachs Group Inc. raised its holdings in shares of Alignment Healthcare by 79.1% in the first quarter. Goldman Sachs Group Inc. now owns 972,715 shares of the company’s stock worth $18,112,000 after acquiring an additional 429,703 shares during the last quarter. Woodline Partners LP acquired a new position in shares of Alignment Healthcare in the first quarter worth $2,142,000. Finally, UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC lifted its position in shares of Alignment Healthcare by 16.9% in the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 307,655 shares of the company’s stock valued at $5,729,000 after acquiring an additional 44,452 shares in the last quarter. 86.19% of the stock is owned by hedge funds and other institutional investors.

About Alignment Healthcare

Alignment Healthcare, Inc (NASDAQ: ALHC) is a health care company specializing in value-based care for Medicare Advantage beneficiaries. The company leverages an integrated care model that combines in-home clinical services, telehealth capabilities and digital health tools to manage chronic conditions, improve outcomes and enhance patient experience.

At the core of Alignment Healthcare’s approach is a proprietary technology platform that aggregates real-time clinical and claims data to support preventive care, risk stratification and personalized care plans.